Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.
The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.
Overview
Obesity drugs might be the hottest growth story in healthcare right now. GLP-1 agonists and similar drugs encourage weight loss for managing obesity and treating type 2 diabetes. The viral success of Mounjaro and Zepbound has made Eli Lilly (NYSE: LLY) a home run winner. The stock's 160% run over the past three years has been a windfall for investors.
But this story isn't over. Research from Morgan Stanley estimates that the obesity drug market will continue to surge, from approximately $15 billion in 2024 to as much as $150 billion by 2035. Here's how Eli Lilly can continue to lead over the next decade, and how that could impact the stock.
Details
Source
Originally published at www.fool.com.